This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

Recurrent miscarriage: diabetes drug could ... An existing drug can be used to improve the womb for pregnancy, ... (08 Jan 2020)
Nerve Stimulation May Benefit Women with ... A treatment involving electrical nerve stimulation helped women ... (08 Jan 2020)
Cancer drugs could potentially treat COPD, ... New research from the University of Sheffield shows a certain ... (08 Jan 2020)
Tea drinkers live longer Drinking tea at least three times a week is linked with a longer ... (08 Jan 2020)
How diet affects mental health – what’s the ... A new expert review confirms that diet significantly influences ... (08 Jan 2020)


JUser: :_load: Unable to load user with ID: 5232
Friday, 06 September 2019 11:54

Bypass surgery and coronary stenting yield comparable 10-year survival Featured

Rate this item
(0 votes)

Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomised patients with de novo three-vessel and left main coronary artery disease, according to late breaking results from the SYNTAX Extended Survival study presented at ESC Congress 2019 together with the World Congress of Cardiology and published in The Lancet.

Prespecified subgroup analyses showed that surgery provided a survival benefit in patients with three-vessel disease and more complex coronary artery disease, while no treatment differences were found in patients with left main disease.

Ischaemic heart disease is the top cause of death globally. Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are options for patients requiring revascularisation. European guidelines advise discussing these patients in a multidisciplinary Heart Team.3

Individual randomised trials comparing PCI with drug-eluting stents and CABG have not shown a survival benefit for either therapy at mid-term follow-up (e.g. up to five years). The SYNTAX trial was the first large-scale multicentre, randomised study in patients with de novo three-vessel and left main coronary artery disease that underwent PCI with drug-eluting stents or CABG. When clinical equipoise between PCI and CABG was presumed by the Heart Team, 1,800 patients were randomly assigned to PCI with paclitaxel-eluting stents (n=903) or CABG (n=897). Survival curves started to diverge after one-year follow-up4 and continued to diverge up to five years, but without reaching statistical significance.

The SYNTAX Extended Survival (SYNTAXES) study examined 10-year all-cause death rates in patients with de novo three-vessel and left main coronary artery disease randomised to PCI with drug-eluting stents or CABG in the SYNTAX trial. All 85 SYNTAX sites from 18 North American and European countries were contacted to provide survival data, which was obtained from healthcare records and national death registries. Completeness of follow-up was achieved in 94% of patients and was well-balanced between the CABG and PCI arms.

At 10-year follow-up, there was no survival difference between PCI with drug-eluting stents and CABG in the overall cohort of patients. There were 244 deaths after PCI and 211 after CABG (hazard ratio [HR] 1.17; 95% confidence interval [CI] 0.97–1.41; p=0.092).

When analyses were conducted according to prespecified subgroups, CABG provided a 10-year survival benefit over PCI in patients with three-vessel disease (151 deaths after PCI versus 113 after CABG; HR 1.41; 95% CI 1.10–1.80; p=0.006). CABG also provided a survival benefit in patients with increasingly complex coronary artery disease (defined by higher SYNTAX scores) – this was observed in the overall cohort and in those with three-vessel disease. In the subgroup of patients with left main coronary artery disease, no survival differences existed between PCI and CABG (93 patients died after PCI versus 98 after CABG; HR 0.90; 95% CI 0.68–1.20; p=0.47). This resulted in a treatment-by-subgroup interaction according to the presence or absence of left main coronary artery disease (p for interaction=0.019). Furthermore, CABG and PCI resulted in comparable 10-year survival in patients with and without diabetes.

First author Dr Daniel Thuijs of the Erasmus University Medical Centre, Rotterdam, the Netherlands said: “The SYNTAX Extended Survival study presents robust, clinically relevant, and complete 10-year randomised survival data and can aid a multidisciplinary Heart Team discussion in the process of deciding on the optimal treatment strategy for a patient with coronary artery disease requiring revascularisation.”

Read 261 times

Latest news


  • Nescafé 3 in1 LifeCycle HEROES return from South Asia

    Donations for Nescafé 3in1 LifeCycle Challenge 2019 can be sent via sms: 5061 7370 = €2.33; 5061 8920 = €6.99; 5061 9229 = €11.65; or via a call to 5160 2020 = €10, 5170 2005 = €15; and 5180 2006 = €25. Bank details are Swift code VALLMTMT, IBAN number MT 18 VALL 22013000000014814521017, Bank name Bank of Valletta, Account number 14814521017.

  • Give a Gift this Christmas which gives back

    The story of medicine is the story of civilization, from an ancient craft of primitive magic and religion to the sophisticated field of science and technology of today.



Connect with other Medical Professionals on fb in a closed facebook group


We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…